Company: ICUI
Filing Date: 2025-11-06
Form Type: 10-Q
Source: 0000883984-25-000035
Chunk: 189

Company: ICU MEDICAL INC/DE
Filing Date: 2025-11-06
Form: 10-Q
Item: Item 8
Chunk 189
---
ows from Investing Activities

    The following table summarizes the changes in our investing cash flows (in thousands):

Nine months ended September 30,20252024ChangeInvesting Cash Flows:Purchases of property, plant and equipment$(63,397)$(55,292)$(8,105)(1)Proceeds from sale of business211,185 — $211,185 (2)Proceeds from sale of assets42 695 (653)Intangible asset additions(7,210)(8,317)1,107 Proceeds from sale of investment securities— 500 (500)(3)Net cash provided by (used in) investing activities$140,620 $(62,414)$203,034 

_______________________________

(1)    Our purchases of property, plant and equipment may vary from period to period based on additional investments needed to support new and existing products and expansion of our manufacturing facilities.

(2)    In 2025, we sold a 60% ownership interest in our IV Solutions business to OPF, see Note 4: Assets Held For Sale and Disposal of Business to our accompanying condensed consolidated financial statements.

(3)    Proceeds from the sale of our investment securities may vary from period to period based on the maturity dates of the investments.

Cash Flows from Financing Activities

    The following table summarizes the changes in our financing cash flows (in thousands):    

54

Nine months ended September 30,20252024ChangeFinancing Cash Flows:Principal payments on long-term debt$(272,750)$(38,250)$(234,500)(1)Proceeds from exercise of stock options5,972 5,883 89 (2)Payments on finance leases(1,543)(775)(768)Payment of contingent earn-out liability— (2,600)2,600 (3)Tax withholding payments related to net share settlement of equity awards(8,719)(11,867)3,148 (4)Net cash used in financing activities$(277,040)$(47,609)$(229,431)

_______________________________

(1)    Relates to scheduled principal payments and prepayments on the Senior Secured Credit Facilities. In March 2025, we prepaid $35.0 million on our Term Loan B. In May 2025, we used $200.0 million received from the sale of a 60% interest in our IV Solutions business to